Watchlist Manager

Watchlist

Price: 10.96 CNY -1.44%

Market Cap: ¥2.6B

T	Tus Pharmaceutical Group Co Ltd SZSE:000590	CN

Income Statement

Currency: CNY

	Dec-2004	Mar-2005	Jun-2005	Sep-2005	Dec-2005	Mar-2006	Jun-2006	Sep-2006	Dec-2006	Mar-2007	Jun-2007	Sep-2007	Dec-2007	Mar-2008	Jun-2008	Sep-2008	Dec-2008	Mar-2009	Jun-2009	Sep-2009	Dec-2009	Mar-2010	Jun-2010	Sep-2010	Dec-2010	Mar-2011	Jun-2011	Sep-2011	Dec-2011	Mar-2012	Jun-2012	Sep-2012	Dec-2012	Mar-2013	Jun-2013	Sep-2013	Dec-2013	Mar-2014	Jun-2014	Sep-2014	Dec-2014	Mar-2015	Jun-2015	Sep-2015	Dec-2015	Mar-2016	Jun-2016	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025	Dec-2025
Revenue
Interest Expense	16	0	0	0	18	0	0	0	21	0	0	0	14	0	0	0	15	0	0	0	9	0	0	0	8	0	0	0	5	0	0	0	3	0	0	0	0	0	0	0	4	0	0	0	4	0	0	0	3	0	0	0	1	0	0	0	1	2	2	2	2	0	0	0	0	0	0	0	0	1	1	1	1	2	3	3	4	4	4	4	4	4	0	0	0
Revenue	267 N/A	272 +2%	276 +1%	278 +1%	271 -3%	275 +1%	279 +1%	296 +6%	287 -3%	269 -6%	240 -11%	221 -8%	208 -6%	216 +4%	245 +13%	232 -5%	237 +2%	245 +4%	253 +3%	267 +5%	274 +3%	289 +5%	277 -4%	299 +8%	312 +4%	330 +6%	346 +5%	354 +2%	344 -3%	354 +3%	379 +7%	354 -7%	363 +3%	365 +0%	340 -7%	323 -5%	256 -21%	215 -16%	175 -19%	174 -1%	203 +17%	235 +16%	270 +14%	285 +6%	295 +4%	300 +2%	298 -1%	295 -1%	317 +8%	295 -7%	313 +6%	311 -1%	344 +11%	331 -4%	284 -14%	254 -11%	186 -27%	215 +16%	241 +12%	271 +13%	315 +16%	288 -9%	274 -5%	277 +1%	275 -1%	291 +6%	308 +6%	315 +2%	301 -4%	316 +5%	331 +4%	456 +38%	351 -23%	731 +109%	734 +0%	625 -15%	405 -35%	381 -6%	361 -5%	346 -4%	343 -1%	331 -3%	339 +2%	352 +4%	338 -4%
Gross Profit
Cost of Revenue	(141)	(140)	(146)	(145)	(142)	(150)	(157)	(179)	(185)	(173)	(148)	(122)	(103)	(106)	(118)	(117)	(119)	(122)	(127)	(131)	(135)	(142)	(138)	(145)	(138)	(142)	(148)	(152)	(155)	(163)	(189)	(179)	(180)	(185)	(160)	(156)	(145)	(113)	(93)	(88)	(99)	(115)	(127)	(133)	(135)	(138)	(142)	(145)	(152)	(149)	(157)	(151)	(151)	(159)	(138)	(130)	(99)	(118)	(130)	(142)	(149)	(137)	(129)	(131)	(122)	(137)	(143)	(145)	(135)	(152)	(175)	(296)	(172)	(439)	(426)	(316)	(193)	(192)	(190)	(187)	(183)	(187)	(191)	(194)	(188)
Gross Profit	127 N/A	132 +4%	130 -1%	133 +2%	129 -3%	125 -3%	122 -3%	117 -4%	102 -13%	97 -5%	93 -4%	100 +8%	105 +5%	111 +6%	127 +14%	115 -9%	118 +2%	123 +4%	126 +3%	136 +8%	139 +2%	147 +6%	139 -6%	155 +12%	174 +12%	187 +8%	198 +6%	202 +2%	188 -7%	191 +2%	190 -1%	175 -8%	183 +5%	179 -2%	180 +0%	167 -7%	111 -34%	102 -7%	82 -20%	86 +5%	104 +21%	120 +16%	142 +18%	152 +7%	160 +6%	162 +1%	156 -4%	150 -4%	165 +10%	146 -11%	157 +7%	160 +2%	192 +20%	173 -10%	146 -15%	123 -16%	86 -30%	96 +11%	111 +15%	129 +17%	167 +29%	151 -9%	145 -4%	146 +1%	153 +4%	155 +1%	166 +7%	170 +2%	166 -2%	164 -1%	155 -5%	160 +3%	178 +11%	292 +64%	308 +5%	309 +1%	211 -32%	189 -11%	171 -9%	160 -7%	160 +0%	145 -10%	148 +2%	158 +7%	149 -5%
Operating Income
Operating Expenses	(102)	(102)	(99)	(100)	(103)	(103)	(100)	(88)	(79)	(72)	(60)	(66)	(57)	(62)	(75)	(68)	(90)	(88)	(108)	(128)	(206)	(216)	(201)	(188)	(112)	(112)	(123)	(134)	(119)	(115)	(82)	(81)	(119)	(119)	(153)	(164)	(202)	(251)	(234)	(221)	(165)	(183)	(201)	(191)	(130)	(130)	(126)	(139)	(146)	(89)	(141)	(146)	(174)	(161)	(143)	(139)	(121)	(132)	(140)	(139)	(138)	(108)	(121)	(118)	(127)	(123)	(130)	(131)	(130)	(138)	(144)	(153)	(161)	(269)	(277)	(283)	(199)	(184)	(193)	(187)	(207)	(318)	(312)	(314)	(177)
Selling, General & Administrative	(102)	(102)	(99)	(99)	(103)	(102)	(98)	(87)	(69)	(63)	(55)	(58)	(54)	(60)	(68)	(64)	(77)	(78)	(83)	(92)	(112)	(119)	(122)	(118)	(108)	(112)	(110)	(118)	(97)	(94)	(96)	(100)	(108)	(132)	(142)	(150)	(191)	(184)	(168)	(156)	(151)	(170)	(186)	(178)	(116)	(123)	(119)	(131)	(131)	(130)	(138)	(143)	(164)	(161)	(143)	(137)	(113)	(123)	(129)	(127)	(125)	(120)	(114)	(111)	(117)	(119)	(126)	(128)	(124)	(132)	(138)	(146)	(143)	(254)	(262)	(266)	(181)	(185)	(180)	(175)	(187)	(190)	(184)	(184)	(150)
Research & Development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(2)	0	0	0	(3)	0	0	0	(4)	0	0	0	(5)	0	0	0	(6)	0	0	(2)	(6)	0	0	(2)	(7)	(7)	(9)	(10)	(9)	(9)	(8)	(9)	(9)	(10)	(9)	(9)	(8)	(9)	(10)	(10)	(13)	(21)	(22)	(22)	(12)	(12)	(13)	(13)	(12)	(14)	(15)	(15)	(11)
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(9)	0	0	0	(9)	0	0	0	(11)	0	0	0	(10)	0	0	0	(10)	0	0	0	(10)	0	0	0	(9)	0	0	0	(8)	0	0	0	(8)	0	0	0	(8)	0	0	0	(11)	0	0	0	(14)	0	0	0	(14)	0	0	0	(20)
Other Operating Expenses	(0)	0	0	(0)	(0)	(0)	(1)	0	(9)	(9)	(6)	(8)	(3)	(2)	(6)	(4)	(13)	(10)	(25)	(35)	(94)	(97)	(78)	(70)	(4)	(0)	(13)	(16)	(22)	(21)	14	20	0	14	(12)	(15)	0	(68)	(67)	(65)	1	(14)	(15)	(14)	2	(7)	(7)	(8)	1	42	(3)	(2)	6	0	0	(1)	8	(2)	(2)	(1)	4	21	1	1	7	6	6	6	11	3	3	3	5	6	6	6	7	13	0	2	6	(114)	(113)	(114)	5
Operating Income	24 N/A	29 +21%	31 +6%	33 +7%	26 -21%	22 -15%	22 0%	29 +32%	23 -20%	24 +5%	33 +33%	34 +5%	48 +40%	49 +2%	52 +7%	47 -10%	28 -40%	35 +24%	19 -47%	9 -54%	(67) N/A	(70) -3%	(62) +11%	(33) +46%	62 N/A	76 +23%	75 -1%	69 -8%	69 +1%	76 +10%	107 +41%	94 -12%	64 -32%	61 -5%	27 -56%	3 -87%	(92) N/A	(149) -63%	(153) -2%	(135) +11%	(62) +55%	(63) -3%	(59) +7%	(40) +33%	30 N/A	33 +7%	30 -7%	11 -64%	20 +79%	58 +193%	16 -73%	14 -11%	18 +31%	12 -38%	4 -69%	(16) N/A	(35) -125%	(35) -1%	(29) +18%	(9) +68%	29 N/A	43 +48%	24 -44%	28 +17%	26 -9%	32 +24%	36 +14%	39 +8%	36 -6%	26 -29%	11 -58%	7 -36%	18 +149%	24 +35%	30 +28%	27 -12%	12 -56%	5 -60%	(22) N/A	(27) -24%	(47) -73%	(174) -267%	(164) +6%	(156) +5%	(28) +82%
Pre-Tax Income
Interest Income Expense	(21)	(22)	(21)	(22)	(23)	(24)	(27)	(26)	(21)	(21)	(12)	(10)	(12)	(8)	(8)	(9)	(9)	(13)	(11)	(6)	(4)	(7)	(10)	(8)	0	9	18	19	15	7	0	(4)	(3)	124	126	126	3	4	4	6	2	3	1	(1)	(1)	0	1	(0)	(3)	0	1	2	4	9	11	11	5	6	5	5	2	6	7	6	5	9	9	11	7	9	9	8	5	10	7	5	1	0	0	(0)	(3)	(3)	(3)	(3)	(2)
Non-Reccuring Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	125	0	0	0	(40)	0	0	0	(11)	0	0	0	0	0	0	0	47	0	47	47	0	0	0	2	(6)	0	1	1	21	0	20	20	(3)	0	1	1	(1)	1	3	2	(1)	3	0	0	8	0	13	13	(119)	(0)	3	4	(21)
Gain/Loss on Disposition of Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(2)	0	0	0	(2)	0	0	0	(1)	0	0	0	0	0	0	0	(0)	0	0	0	0	0	0	0	(2)	0	0	(2)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	(1)	(1)	(1)	(1)	(2)	(2)	(7)	(6)	(1)	(0)	3	(3)	(4)	(4)	(1)	5	7	5	(3)	(2)	(2)	(4)	(3)	(3)	(5)	(6)	(5)	(3)	4	4	3	1	(2)	(2)	(2)	(2)	(37)	(35)	(34)	(37)	(17)	(18)	(18)	(15)	2	2	1	1	3	5	4	4	(0)	(4)	(4)	(4)	(1)	(1)	(1)	(1)	1	1	1	2	(0)	(0)	(0)	(1)	(0)	(0)	(0)	(0)	(0)	(1)	(1)	(1)	10	9	9	9	47	47	47	47	2
Pre-Tax Income	2 N/A	7 +200%	9 +35%	10 +11%	1 -88%	(4) N/A	(12) -234%	(3) +71%	2 N/A	4 +135%	24 +495%	22 -10%	32 +47%	37 +17%	44 +18%	43 -2%	24 -45%	27 +16%	5 -81%	1 -90%	(76) N/A	(80) -6%	(74) +7%	(44) +41%	56 N/A	79 +41%	88 +12%	85 -4%	88 +3%	87 -1%	110 +27%	91 -18%	184 +103%	183 0%	151 -18%	127 -16%	(166) N/A	(181) -9%	(184) -1%	(166) +9%	(88) +47%	(80) +9%	(77) +4%	(56) +27%	31 N/A	34 +10%	32 -6%	12 -63%	66 +452%	63 -6%	68 +8%	67 -1%	22 -67%	17 -22%	11 -39%	(6) N/A	(36) -489%	(30) +15%	(23) +23%	(5) +81%	53 N/A	50 -6%	52 +2%	55 +7%	28 -50%	40 +44%	45 +13%	50 +10%	42 -16%	35 -16%	22 -36%	17 -24%	22 +28%	35 +62%	37 +4%	31 -15%	30 -5%	14 -52%	0 -100%	(6) N/A	(122) -2 101%	(130) -7%	(116) +11%	(109) +6%	(50) +55%
Net Income
Tax Provision	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	3	3	1	(1)	(11)	(12)	(13)	(12)	(7)	(8)	(5)	(6)	(12)	(12)	(11)	(14)	(9)	(10)	(13)	(13)	(16)	(17)	(15)	(13)	(47)	(47)	(46)	(44)	1	4	4	2	2	1	1	1	(9)	(9)	(10)	(11)	(16)	(16)	(17)	(16)	(12)	(12)	(9)	(7)	(2)	(3)	(3)	(5)	(11)	(10)	(11)	(11)	(5)	(6)	(7)	(7)	(6)	(8)	(5)	(5)	(4)	(7)	(8)	(7)	(5)	(4)	(5)	(4)	(5)	(5)	(5)	(5)	(0)
Income from Continuing Operations	2	7	9	10	1	(4)	(12)	(4)	5	7	25	20	21	25	30	31	17	20	(0)	(5)	(88)	(93)	(86)	(59)	47	69	75	72	72	70	95	78	138	136	105	83	(165)	(177)	(180)	(164)	(86)	(78)	(76)	(56)	22	26	23	2	50	46	51	51	10	6	1	(13)	(38)	(33)	(26)	(10)	42	41	41	45	23	34	38	43	35	27	18	12	18	28	29	25	25	10	(5)	(10)	(127)	(135)	(121)	(114)	(50)
Income to Minority Interest	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	5	6	7	7	9	0	0	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(0)	(0)	(0)	(0)	(0)	(0)	0	0	0	0	2	2	2	2	(0)
Equity Earnings Affiliates	3	2	2	2	3	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income (Common)	5 N/A	10 +80%	12 +25%	13 +7%	4 -67%	0 N/A	(10) N/A	(2) +81%	6 N/A	7 +25%	25 +267%	21 -16%	21 -3%	25 +22%	30 +21%	31 +2%	17 -46%	20 +17%	(0) N/A	(5) -2 450%	(88) -1 622%	(93) -6%	(86) +7%	(59) +32%	47 N/A	69 +47%	75 +9%	72 -4%	72 N/A	70 -3%	95 +36%	78 -18%	138 +78%	136 -1%	105 -23%	83 -20%	(165) N/A	(177) -8%	(180) -1%	(164) +9%	(86) +48%	(78) +9%	(76) +3%	(56) +27%	22 N/A	26 +14%	23 -10%	3 -86%	55 +1 573%	52 -5%	57 +9%	57 +0%	19 -67%	14 -27%	9 -38%	(7) N/A	(38) -479%	(33) +14%	(26) +20%	(10) +63%	42 N/A	41 -4%	41 +1%	45 +9%	23 -49%	34 +52%	38 +11%	43 +11%	35 -17%	27 -22%	18 -35%	12 -32%	18 +50%	28 +54%	29 +3%	25 -14%	25 +3%	10 -59%	(5) N/A	(10) -113%	(125) -1 202%	(133) -6%	(119) +11%	(112) +6%	(51) +55%
EPS (Diluted)	0.02 N/A	0.03 +50%	0.04 +33%	0.05 +25%	0.02 -60%	0.01 -50%	-0.03 N/A	0 N/A	0.02 N/A	0.03 +50%	0.11 +267%	0.09 -18%	0.09 N/A	0.1 +11%	0.13 +30%	0.14 +8%	0.07 -50%	0.1 +43%	0.01 -90%	-0.02 N/A	-0.39 -1 850%	-0.41 -5%	-0.38 +7%	-0.25 +34%	0.21 N/A	0.32 +52%	0.34 +6%	0.32 -6%	0.32 N/A	0.31 -3%	0.43 +39%	0.35 -19%	0.62 +77%	0.61 -2%	0.47 -23%	0.38 -19%	-0.74 N/A	-0.79 -7%	-0.8 -1%	-0.73 +9%	-0.38 +48%	-0.34 +11%	-0.34 N/A	-0.25 +26%	0.1 N/A	0.11 +10%	0.1 -9%	0.01 -90%	0.25 +2 400%	0.23 -8%	0.25 +9%	0.25 N/A	0.08 -68%	0.05 -38%	0.03 -40%	-0.03 N/A	-0.16 -433%	-0.13 +19%	-0.1 +23%	-0.03 +70%	0.18 N/A	0.17 -6%	0.17 N/A	0.18 +6%	0.09 -50%	0.14 +56%	0.16 +14%	0.18 +12%	0.15 -17%	0.11 -27%	0.07 -36%	0.05 -29%	0.08 +60%	0.12 +50%	0.12 N/A	0.1 -17%	0.11 +10%	0.04 -64%	-0.02 N/A	-0.04 -100%	-0.52 -1 200%	-0.56 -8%	-0.5 +11%	-0.47 +6%	-0.21 +55%

Income Statement Balance Sheet Cash Flow Statement

Tus Pharmaceutical Group Co Ltd
SZSE:000590

Income Statement

Earnings Waterfall
Tus Pharmaceutical Group Co Ltd

Income Statement
Tus Pharmaceutical Group Co Ltd

See Also

Company

Help

Tools

Stocks

Tus Pharmaceutical Group Co Ltd SZSE:000590

Income Statement

Earnings Waterfall Tus Pharmaceutical Group Co Ltd

Income Statement Tus Pharmaceutical Group Co Ltd

See Also

Company

Help

Tools

Stocks

Tus Pharmaceutical Group Co Ltd
SZSE:000590

Earnings Waterfall
Tus Pharmaceutical Group Co Ltd

Income Statement
Tus Pharmaceutical Group Co Ltd